Cannabinoid-Enhanced VR Therapy With Response-Guided Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing augmented and virtual reality experiences lack effective methods to enhance or complement sensory stimuli, particularly for therapeutic applications in treating mental disorders such as PTSD, anxiety, and other psychological conditions.
Innovation Solution
Administering a cannabinoid compound to a subject before, during, or after an AR or VR experience, combined with sensory stimuli like light exposure or temperature changes, to induce epigenetic modifications and neural network alterations, and using detection methods to adjust dosage based on subject response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional VR or AR experiences are used alone, then the sensory stimulation is limited to visual, auditory, and haptic stimuli, but the therapeutic efficacy for treating mental disorders is insufficient
Solution Approach 1:
The patent combines cannabinoid administration with VR/AR experiences to create a multi-modal therapeutic system. The cannabinoid composition is administered to the subject before or during the VR/AR experience, merging pharmacological intervention with sensory stimulation to enhance therapeutic efficacy for mental disorders such as PTSD, anxiety, and depression.
Solution Approach 2:
The invention creates a composite therapeutic approach by combining cannabinoid compounds (such as CBD, THC, or synthetic analogs) with virtual or augmented reality experiences. This composite intervention leverages both the neuropharmacological effects of cannabinoids and the immersive sensory stimulation of VR/AR to produce synergistic therapeutic effects that address mental disorders more effectively than either modality alone.
2Reliability
If cannabinoid compounds are administered to enhance therapeutic efficacy, then the treatment effectiveness improves, but the complexity of the treatment protocol increases
Solution Approach 1:
The cannabinoid composition is administered to the subject before the VR/AR experience begins, allowing the compound to take effect and prepare the subject's neural and psychological state for the upcoming therapeutic intervention. This preliminary administration simplifies the protocol by establishing the pharmacological foundation before the complex VR/AR session starts.
Solution Approach 2:
The system incorporates detection of the subject's response during or after the VR/AR experience, allowing for real-time or post-session assessment of therapeutic effectiveness. This feedback mechanism enables adjustment of future treatment parameters, optimizing the balance between efficacy and protocol complexity through data-driven personalization.
Data Source
AI summary
The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.